Report: Xarelto (Rivaroxaban) Poised to Become Leading Therapy for Venous Thromboembolism
Market for VTE prophylaxis expected to grow to $7.3 billion in 2022 (August 29)
Decision Resources, a research and advisory firm located in Burlington, Mass., forecasts that Xarelto (rivaroxaban, Bayer/Janssen) will be the sales-leading therapy among the new oral anticoagulants in the combined venous thromboembolism (VTE) markets. According to the company, Xarelto benefits from its first-to-market advantage for VTE treatment/secondary prophylaxis, the removal of the need for bridging with a low-molecular-weight heparin (LMWH) in the VTE treatment/secondary prophylaxis setting, and once-daily dosing.
Eliquis (apixaban, Bristol-Myers Squibb/Pfizer) is expected to be the closest competitor to Xarelto, but its later launch in both the VTE primary prophylaxis and VTE treatment/secondary prophylaxis markets, as well as its twice-daily dosing, will likely limit its sales relative to Xarelto during the 2012 to 2022 forecast period.
The new report forecasts that the combined markets for drugs used for both VTE primary prophylaxis and VTE treatment/secondary prophylaxis will grow to $7.3 billion in 2022 in the U.S., Europe, and Japan.
The new oral anticoagulants are forecast to continue to gain market share at the expense of LMWHs for VTE prevention following orthopedic surgery.
“The anticipated launches of Eliquis, Boehringer Ingelheim’s Pradaxa, and Daiichi Sankyo’s Lixiana for VTE treatment/secondary prophylaxis, along with the previously approved Xarelto, will drive growth of the VTE market through 2022,” said analyst Eamonn O’Connor, PhD. “Growth opportunities for these agents will be restricted to the treatment/secondary prophylaxis market, owing to these agents’ inability, to date, to gain a primary prophylaxis label outside of the orthopedic surgery setting.”
Source: Decision Resources; August 29, 2013.